Trial Profile
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 28 Aug 2023 Status changed from recruiting to discontinued.
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 10 Dec 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.